Puromycin (CL13900) 2HCl

For research use only.

Catalog No.S7417

74 publications

Puromycin (CL13900) 2HCl Chemical Structure

CAS No. 58-58-2

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

Selleck's Puromycin (CL13900) 2HCl has been cited by 74 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
In vitro

The antibiotic puromycin is produced by the actinoniycete, Streptornyces alboniger, and has been used as a tool for studying protein synthesis in a number of systems. [1] Puromycin can be used for the selection of recombinant cells from noncultured cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 M360SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHHIbmI4OiCq NV;hW2N[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiZH;4c5J2[mmlaX6tdoV{cXO2YX70JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1{Nj64N{DPxE1w NVK4W|A4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM{ODdpPkG4N|E{OzB5PD;hQi=>
HepG2 MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWTjSIR3PzJiaB?= Mm\XS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlI{KM7:TT6= M{fZUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{GzN|A4Lz5zOEOxN|MxPzxxYU6=
K562 M4XSZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2XDdFczKGh? Ml[wS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT|U3OiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNlIh|ryPLh?= NYHWTIJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM{ODdpPkG4N|E{OzB5PD;hQi=>
HepG2 M13Remdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoDNO|IhcA>? MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNlEh|ryPLh?= NIPmOJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEWxNlk5PCd-MUi1NVI6QDR:L3G+
Huh7 MWHDfZRwfG:6aXPpeJkh[XO|YYm= MmLOUm9XSVKWSWO6JGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIhmeGG2b3PlcIx2dGG{IHPhdoNqdm:vYTDj[YxtKGyrbnWgLGh2cDdrLDDDR|UxRTZwNkOg{txONg>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe4N{c,OTh3N{m3PFM9N2F-
HEK239 MX;DfZRwfG:6aXPpeJkh[XO|YYm= Mne2O|IhcA>? MkDBR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkO5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0xNjR{IN88UU4> MkjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NUiwOlAoRjJyNUW4NFYxRC:jPh?=
J774A1 Mor2R5l1d3SxeHnjbZR6KGG|c3H5 NFP2ephEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBLPzd2QUGgZ4VtdHNiYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKGG|c3H5MEBKSzVyPUGwJO69VS5? NFPGbGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmzOFY{Pid-MkK5N|Q3OzZ:L3G+
KB3-1 MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPoO|IhcHK| NWjjc4VpT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hU0J|LUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkGg{txONg>? NH\6c2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN|MxPyd-MUizNVM{ODd:L3G+
HepG2/Dox M2ezeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzyTms4OiCqcoO= M2L1TGdzd3e2aDDpcohq[mm2aX;uJI9nKG23bITp[JJ2\yC{ZYPpd5RidnRiaIXtZY4hUGWyR{KvSI95KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCyNE4zKM7:TT6= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDVzMkm4OEc,OTh3MUK5PFQ9N2F-
HEK293 NX3ifFIxS3m2b4TvfIlkcXS7IHHzd4F6 MlOwO|IhcHK| MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdi2kYYPl[EBxdGG2ZTDy[YFl\XJiYX7hcJl{cXNuIFnDOVAhRSByLkO2NUDPxE1w M1nye|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWxOVM4Lz5{Nk[1NVU{PzxxYU6=
HEK293 M4f2[GN6fG:2b4jpZ4l1gSCjc4PhfS=> NVr1OZByPzJiaILz M{jFVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUhfmmjYnnsbZR6KGG|c3H5MEBKSzVyIE2gNE4{PTB3IN88UU4> NWK5W2RLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjNpPkK3NFYxPzZ|PD;hQi=>
A549 MXHDfZRwfG:6aXPpeJkh[XO|YYm= MkDPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{whUUN3MDC9JFAvPiEQvF2u NHGzSIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4PVIyPCd-MkewPFkzOTR:L3G+
PC3 MoTHR5l1d3SxeHnjbZR6KGG|c3H5 Mo\YR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzMEBKSzVyIE2gNE44KM7:TT6= MlPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOEmyNVQoRjJ5MEi5NlE1RC:jPh?=
HEK293 NEfzOYtEgXSxdH;4bYNqfHliYYPzZZk> MoDpR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gNE4xODB|NTFOwG0v MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJzMkC3NEc,Ojd{MUKwO|A9N2F-
HEK293 NFrM[YdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlvlO|IhcHK| M1HrT2dzd3e2aDDpcohq[mm2aX;uJI9nKEiHS{K5N{Bk\WyuczDh[pRmeiB5MjDodpMh[nliUILld5RwSmy3ZTDzeIFqdmmwZzDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkO2JO69VS5? Mk[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMEGwOlcoRjJ6MECxNFY4RC:jPh?=
HEK293 MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYr4OpNQT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSFXLNlk{KGOnbHzzMEBKSzVyIE2gNE4{QTlizszNMi=> NXjLWHVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NFAzOzFpPkK4OFAxOjNzPD;hQi=>
SU-DHL10 NGq0W5hEgXSxdH;4bYNqfHliYYPzZZk> M2fHWlczKGi{cx?= MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWU1FUExzMDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfHKnLVfsc{BtfW2rbnXzZ4VvfCCjc4PhfUwhS0N3MDC9JFAvOTFizszNMi=> M2DKN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKzNVA{Lz5{OEWyN|ExOzxxYU6=
MIAPaCa2 MVzDfZRwfG:6aXPpeJkh[XO|YYm= NUPvNpZtPzJiaILz M1;jNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1KSVCjQ3GyJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCFQ{WwJF0hOC5{IN88UU4> M2Pxb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKzNVA{Lz5{OEWyN|ExOzxxYU6=
MDA-MB-231 NE\zO3REgXSxdH;4bYNqfHliYYPzZZk> MYm3NkBpenN? MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCFQ{WwJF0hOC52ODFOwG0v NFW4OVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWyN|ExOyd-Mki1NlMyODN:L3G+
HEK293 NILFS4VEgXSxdH;4bYNqfHliYYPzZZk> NVjxTXhsPzJiaILz Ml\uR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KEGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC52NjFOwG0v MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd5NESyO{c,Ojh5N{S0Nlc9N2F-
HL60 MVzBcpRqeGG{YYPpeIlkKGG|c3H5 MoHQO|IhcHK| M2XyR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDFR|UxKD1iMD6wOVUh|ryPLh?= M1jhS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OECzNFQ4Lz5{OEiwN|A1PzxxYU6=
MOLT4 NE\1VJRCdnSrcHHyZZNqfGmlIHHzd4F6 MlzmO|IhcHK| MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFXDOVAhRSByLkG3JO69VS5? NEn3doQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiwN|A1Pyd-Mki4NFMxPDd:L3G+
Vero NYnlWWExS3m2b4TvfIlkcXS7IHHzd4F6 MUW3NkBpenN? NIfHSI5EgXSxdH;4bYNqfHliYXfhbY5{fCCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEKuPEDPxE1w NXSwSJF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NFMxPDdpPkK4PFA{ODR5PD;hQi=>
HEK293 NV\O[ppzS3m2b4TvfIlkcXS7IHHzd4F6 MoSxO|IhcHK| MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdiCmeXWgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjR3IN88UU4> NUX0TIl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyN|Y1QTJpPkK5NlM3PDl{PD;hQi=>
HEK293T NFLmdmpEgXSxdH;4bYNqfHliYYPzZZk> MonWO|IhcHK| MkniR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGVMOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHz1cYlv\XOlZX7j[UBie3OjeTygR2M2OCB;IECuOFIh|ryPLh?= NGC1OlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HCT8 M3TWbGFvfGmyYYLhd4l1cWNiYYPzZZk> MmHGOFghcHK| NFfjemdCdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBDT0ZiaX7m[YN1\WRiaX6gbJVu[W5iSFPUPEBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCISWTDM2RCWElic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC53NTFOwG0v MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4OUW3OUc,Ojl2Nkm1O|U9N2F-
HCT8 NVTKWGtJSW62aYDhdoF{cXSrYzDhd5NigQ>? NFntZVQ1QCCqcoO= M4TEcmFvfGmyYYLhd4l1cWNiYXP0bZZqfHliYXfhbY5{fCCFconweI9{eG:{aXTpeY0heGG{doXtJHNRVCCrbn\lZ5Rm\CCrbjDoeY1idiCKQ2S4JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE[LVFOvSGFRUSC|dHHpcolv\yCkYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEWFNUCgQUAxNjZizszNMi=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4OUW3OUc,Ojl2Nkm1O|U9N2F-
HepG2 MXnDfZRwfG:6aXPpeJkh[XO|YYm= M{LDZVczKGi{cx?= MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGy3bXnu[ZNk\W6lZTDhd5NigSxiQ1O1NEA:KDBwOEOg{txONg>? MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nkm1O|UoRjJ7NE[5OVc2RC:jPh?=
HCT8 MlXPR5l1d3SxeHnjbZR6KGG|c3H5 NHvoXnVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{NCCHQ{WwJF0hPi5zIN88UU4> MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nkm1O|UoRjJ7NE[5OVc2RC:jPh?=
HEK293 NVX0XVFTS3m2b4TvfIlkcXS7IHHzd4F6 MmK5O|IhcHK| M1K3[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuOFYh|ryPLh?= Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{O2NVEoRjJ7NUOzOlEyRC:jPh?=
HEK293 M4jUVWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2Hx[FczKGi{cx?= MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDISWszQTNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBlgWViYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC52IN88UU4> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl4OUK2Nkc,Ojl7NkmyOlI9N2F-
A549 MnzrR5l1d3SxeHnjbZR6KGG|c3H5 NEjmZYM1QCCqcoO= M{XtZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzMEBKSzVyIE2gNE4{KM7:TT6= M3r0b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEG4O|Y{Lz5|MESxPFc3OzxxYU6=
PC3 NEi3eZREgXSxdH;4bYNqfHliYYPzZZk> NILMPVA1QCCqcoO= MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|LDDJR|UxKD1iMD6zJO69VS5? M4O4WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEG4O|Y{Lz5|MESxPFc3OzxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cyclin D1 / CDK4; 

PubMed: 31022952     


(C) Effect of puromycin on cyclin D1 and CDK4 in a concentration-dependent manner in HCT116 and H1299 cells. Cells were treated with puromycin (0.25 or 0.5 μg/mL) for 24 h and subjected to Western blotting with antibodies of cyclin D1, CDK4 and β actin. (D) Effect of puromycin on cyclin D1 and CDK4 in a time-dependent manner in HCT116 and H1299 cells. Cells were treated with 0.5 μg/mL puromycin for 3, 6, 12 or 24 h and subjected to Western blotting with antibodies of cyclin D1, CDK4, and β-actin.

PARP / Bcl-xL / Bcl-2 / p-Akt / Akt; 

PubMed: 31022952     


(E) Effect of puromycin on Poly (ADP-ribose) polymerase (PARP), Bcl-xL, Bcl-2, AKT, and p-AKT (v-akt murine thymoma viral oncogene homolog) in a concentration-dependent manner in HCT116 and H1299 cells. Cells were treated with puromycin (0.25 or 0.5 μg/mL) for 24 h and subjected to Western blotting with antibodies of PARP, Bcl-xL, Bcl-2, p-AKT, AKT, and β-actin. (F) Effect of puromycin on PARP, Bcl-xL, Bcl-2, AKT, and p-AKT in a time-dependent manner in HCT116 and H1299 cells. Cells were treated with 0.5 μg/mL of puromycin for 3, 6, 12 or 24 h and subjected to Western blotting with antibodies of PARP, Bcl-xL, Bcl-2, p-AKT, AKT, and β-actin.

p53 / p21 / c-Myc; 

PubMed: 31022952     


Effect of puromycin on p53, p21, and c-Myc in a concentration and time-dependent manner in HCT116 cells. HCT116 cells were exposed to various concentrations of puromycin (0.25 or 0.5 μg/mL) for 24 h and then subjected to Western blotting with antibodies of p53, p21, and c-Myc. Also, HCT116 cells were treated with 0.5 μg/mL puromycin for 6, 12, or 24 h and subjected to Western blotting.

31022952
Growth inhibition assay
Cell viability; 

PubMed: 31022952     


Cytotoxicity of puromycin in HCT116, SW620, HCT15, and H1299 cells in a concentration-dependent manner by 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Data represent means ± SD. *, p < 0.05, **, p < 0.01, ***, p< 0.001 vs. untreated control.

31022952

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (183.67 mM)
Water 100 mg/mL warmed (183.67 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 544.43
Formula

C22H29N7O5.2HCl

CAS No. 58-58-2
Storage powder
in solvent
Synonyms N/A
Smiles CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antineoplastic and Immunosuppressive Antibiotics Products

Tags: buy Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl supplier | purchase Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl cost | Puromycin (CL13900) 2HCl manufacturer | order Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID